Please assess the completion status of the following clinical trial:

Trial Title: Noninferiority Oral Tranexamic Acid vs Intravenous Administration in Total Hip Arthroplasty

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~- ASA physical status 1, 2 and 3 scheduled for primary total hip arthroplasty~Exclusion Criteria:~* Renal failure with serum creatinine level higher than 1,40 mg/dL~* Thromboembolic events in last 12 months before surgery~* Pregnancy~* Congenital or acquired coagulation diseases~* History of gastric surgery that could lead to malabsorption~* Diabetic gastro-paresis

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 90 Years
- Healthy Volunteers: f

Study Arms:
- Oral Tranexamic Acid (Type: ACTIVE_COMPARATOR): 128 patients scheduled for primary total hip arthroplasty
- Intravenous Tranexamic Acid (Type: ACTIVE_COMPARATOR): 128 patients scheduled for primary total hip arthroplasty

Based on this trial design, predict the completion outcome and termination type (if applicable).